

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number  
**WO 01/45681 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00**

(21) International Application Number: **PCT/GB00/04872**

(22) International Filing Date:

18 December 2000 (18.12.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/172,786 21 December 1999 (21.12.1999) US

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).**

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHAPDELAINE, Marc, Jerome [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). KNAPPENBERGER, Katherine [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). STEELMAN, Gary [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). SUCHARD, Suzanne [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). SYGOWSKI, Linda [US/US]; 1800 Concord Pike, Wilmington, DE**

19850-5437 (US). **URBANEK, Rebecca [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). VEALE, Chris, Allan [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US).**

(74) Agent: **DENERLEY, Paul, Millington; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**


(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CD45 INHIBITORS**



(57) Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q<sup>1</sup> at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C<sub>1</sub>-C<sub>3</sub>) alkyl and C(O)phenyl, and Q<sup>2</sup> is selected from hydrogen, halogen, O-(C<sub>1</sub>-C<sub>3</sub>)alkyl, O-(C<sub>1</sub>-C<sub>3</sub>)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO<sub>2</sub> or halogen, and indolyl may be substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl or phenyl.

WO 01/45681 A2

## **CD45 INHIBITORS**

### **Background**

### **Field of the Invention**

5           Compounds, compositions and methods for the treatment of immunologically-related diseases and disorders such as autoimmune disorders and organ graft rejection.

### **Related Art**

          Action of the immune system is known to be involved in immunologically-related diseases and disorders such as autoimmune disorders and in organ graft rejection ("OGR").

10   Hematopoietic, thymus-derived cells, (so-called "T cells") have an important and pervasive role as regulators and effectors of the functions of the immune system. Hematopoietic cells, and T cells in particular have on their surfaces a major transmembrane glycoprotein designated CD45, characterized by a cluster of antigenic determinants. CD45 is also known as leukocyte common antigen ("LCA"). The cytosolic portion of CD45 has protein tyrosine

15   phosphatase ("PTP") activity and CD45 activity is known to be essential for TCR initiated T cell activation. Studies in CD45-deficient cell lines have shown that CD45 is a positive regulator of the T-Cell Receptor ("TCR") and that CD45 functions in TCR regulation by dephosphorylating the src kinases p56<sup>lck</sup> and p59<sup>fyn</sup>, which allows autophosphorylation of the positive regulatory site on these enzymes; these reactions lead to downstream events and

20   ultimately to T cell activation.

          Available treatments for autoimmune disorders and OGR have therapeutic disadvantages. For example, Cyclosporin A, the drug most commonly used to treat OGR, has renal and CNS toxicity.


### **Summary of the Invention**

25           Potent inhibitors of CD45 have been discovered. Such inhibitors are useful for the treatment of various autoimmune disorders as well as for treatment of OGR. Inhibition of the phosphatase activity of CD45 by compounds of the present invention has been shown by incubating the cytosolic portion of CD45 with the compounds and *p*-nitrophenyl phosphate (*p*NPP), a phosphatase substrate. Spectrophotometric monitoring has shown that the

30   liberation of *p*-nitrophenol from the substrate by CD45 is inhibited in the presence of the compounds disclosed herein. Inhibition of the phosphatase activity of CD45 by compounds of the present invention has also been shown using a p56<sup>lck</sup> carboxy-terminal phosphorylated

peptide as a substrate. Compounds of the present invention have also been shown to inhibit proliferation of T cells in a T-cell proliferation assay.

Compounds of the present invention are naphthalenediones in accord with structural diagram I:



I

wherein:

$Q^1$  at each occurrence is independently selected from hydrogen, hydroxy, halogen,  $C(O)O(C_1-C_3)alkyl$  and  $C(O)phenyl$ , and

10  $Q^2$  is selected from hydrogen, halogen,  $O-(C_1-C_3)alkyl$ ,  $O-(C_1-C_3)alkenyl$ , phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with  $NO_2$  or halogen, and indolyl may be substituted with  $(C_1-C_3)alkyl$  or phenyl.

Particular compound of the invention are 4-(4-bromo-phenyl)-[1,2]naphthoquinone; 4-(3,5-dichloro-phenyl)-[1,2]naphthoquinone; 4-(3-nitro-phenyl)-[1,2]naphthoquinone; 5,6-dioxo-5,6-dihydro-naphthalene-1-carboxylic acid methyl ester, and 5,6-dioxo-5,6-dihydro-naphthalene-2-carboxylic acid methyl ester.

Compounds of the present invention are ligands of CD45 which, when bound, inhibit the activity of the protein tyrosine phosphatase (PTP) activity of the cytosolic portion of CD45. Binding of a compound of the present invention to CD45 inhibits the activity of CD45  
20 essential for TCR initiated T cell activation. Thus, compounds of the invention inhibit the positive regulation of the TCR that leads to downstream events and T cell activation. Compounds of the present invention are useful to suppress the action of the immune system in immunologically-related diseases and disorders such as autoimmune disorders and organ graft rejection and to inhibit the action of T cells as functional regulators and effectors of the  
25 immune system.

The present invention also encompasses compositions made with compounds described herein useful for the treatment of immunologically-related diseases and disorders and methods utilizing such compositions for treating such disorders.

**Detailed Description of the Invention**

As used herein, (C<sub>1</sub>-C<sub>4</sub>)alkyl has its conventionally-understood meaning and particularly means linear or branched hydrocarbon chains having from one to four carbon atoms and thus includes methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 5 tert-butyl, and the like.

As used herein, halo(C<sub>1</sub>-C<sub>4</sub>)alkyl has its conventionally-understood meaning and particularly means (C<sub>1</sub>-C<sub>4</sub>)alkyl as used herein wherein hydrogen atoms have been replaced by halogen atoms and thus includes monochloromethyl, trifluoromethyl, difluoroethyl, trifluoropropyl, perfluoro(C<sub>1</sub>-C<sub>4</sub>)alkyl, and the like.

10 As used herein, perfluoro(C<sub>1</sub>-C<sub>4</sub>)alkyl has its conventionally-understood meaning and particularly means (C<sub>1</sub>-C<sub>4</sub>)alkyl as used herein wherein each hydrogen atom has been replaced by a fluorine atom and thus includes trifluoromethyl.

As used herein, (CH<sub>2</sub>)<sub>n</sub> has its conventionally-understood meaning and particularly means linear hydrocarbon chains having from one to n carbon atoms and thus includes 15 methylene, ethylene, propylene, n-butylene groups, and the like.

As used herein, the terms halogen, halo, or halide have their conventionally-understood meanings and particularly mean chlorine, bromine, iodine or fluorine.

As used herein, the term "from the range 1 to 6" or the like, means any integral value in the stated range, in this example 1, 2, 3, 4, 5 or 6.

20 Definitions of terms:

DMF, *N,N*-dimethylformamide; THF, tetrahydrofuran; TLC, thin-layer chromatography; NMR, nuclear magnetic resonance; TFA, trifluoroacetic acid; HPLC, high performance liquid chromatography; DMAP, 4-dimethylaminopyridine; DMSO, dimethylsulfoxide; IC<sub>50</sub>, concentration giving 50% inhibition; CC<sub>50</sub>, concentration giving 50% 25 cytotoxicity; ND, not determined.

HPLC method used: Analytical HPLC using an HP 1100 HPLC, with a C<sub>18</sub> Dynamax column (5 cm x 4.6 mm, 3 μM particle size, 100 Å pore size), flow rate of 0.5 mL/min, 20%-60% CH<sub>3</sub>CN in H<sub>2</sub>O over 7.5 min, holding at 60% CH<sub>3</sub>CN for 2.5 min, while monitoring at 254 and 210 nm.

30 **Examples**

Example 1: [1,2]-Naphthoquinone was purchased from Acros Organics and used as received.

Examples 2 to 4:

The compounds of examples 2 to 4 were prepared substantially in accordance with the procedures disclosed in Takuwa, A.; Soga, O.; Iwamoto, H.; Maruyama, K. *Bull. Chem. Soc. Jpn.* **1986**, *59*, 2959-2961, which procedures are incorporated herein by reference. The

5 physical properties of the compounds are disclosed in the reference.

Example 2: 4-Ethoxy-[1,2]naphthoquinone.

Example 3: 4-Methoxy-[1,2]naphthoquinone.

Example 4: 4-Allyloxy-[1,2]naphthoquinone.

Examples 5 and 6:

10 The compounds of examples 5 and 6 were prepared substantially in accordance with the procedures disclosed in Perumal, P. T.; Bhatt, M. V. *Synthesis* **1980**, 943-945, which procedures are incorporated herein by reference. The physical properties of the compounds are disclosed in the reference.

Example 5: 4-Chloro-[1,2]naphthoquinone.

15 Example 6: 4-Bromo-[1,2]naphthoquinone.

Examples 7 and 8:

The compounds of examples 7 and 8 were prepared substantially in accordance with the procedures disclosed in Henrion, J.-C.; Jacquet, B.; Hocquaux, M.; Barre, G.; Hedayatullah, M.; Lion, C. *Bull. Soc. Chim. Belg.* **1996**, *105*, 415-418, which procedures are

20 incorporated herein by reference. The physical properties of the compounds are disclosed in the reference.

Example 7: 4-(1-Methyl-1*H*-indol-3-yl)-[1,2]naphthoquinone.

Example 8: 4-(2-Phenyl-1*H*-indol-3-yl)-[1,2]naphthoquinone.

Example 9: 4-(2-Chloro-phenyl)-[1,2]naphthoquinone:

25 To a solution of 4-bromo-[1,2]naphthoquinone (350 mg, 1.48 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added 2-chlorophenylboronic acid (231 mg, 1.48 mmol). followed by tri-*o*-tolylphosphine (45 mg, 148 µmol) and K<sub>2</sub>CO<sub>3</sub> (614 mg, 4.44 mmol). The mixture was deoxygenated with bubbling N<sub>2</sub> for about ten minutes, at which time the N<sub>2</sub> line was removed and *tris*(dibenzylideneacetone)dipalladium(0) (68 mg, 74 µmol) was added. The resultant

30 mixture was heated to reflux for 2 hours under N<sub>2</sub>, at which point no starting bromide was detectable by TLC (hexanes:ethyl acetate, 1:1, v/v). The mixture was cooled to room temperature and the THF evaporated under reduced pressure. The dried material was

dissolved in ethyl acetate, washed sequentially with saturated aqueous ammonium chloride, H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. The isolated material was chromatographed on silica gel (hexanes-ethyl acetate, 4:1, v/v) and dried to yield the product, 4-(2-chloro-phenyl)-[1,2]naphthoquinone, as an orange solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.21 (1H, dd, J = 6.9, 2.1 Hz), 7.56-7.52 (3H, m), 7.48-7.44 (2H, m), 7.44 (1H, m), 6.91 (1H, dd, J = 2, 6 Hz), 6.39 (1H, s); HPLC: 7.45 min.

Compounds of examples 10 to 14 inclusive were made by the method of Example 9, by utilizing the appropriate boronic acid.

Example 10: 4-(4-Bromo-phenyl)-[1,2]naphthoquinone:

10 Orange solid; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.22 (1H, dd, J = 1.8, 7.2 Hz), 7.67 (2H, d, J = 6.6 Hz), 7.63-7.60 (2H, m), 7.33 (2H, d, J = 6.6 Hz), 7.25 (1H, dd, J = 2, 8 Hz), 6.41 (1H, s); HPLC: 8.25 min.

Example 11: 4-Phenyl-[1,2]naphthoquinone:

15 Orange-red solid; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.22 (1H, dd, J = 1.8, 7.2 Hz), 7.62-7.52 (5H, m), 7.46-7.44 (2H, m), 7.30 (1H, dd, J = 1.2, 7.5 Hz), 6.43 (1H, s); HPLC: 6.90 min

Example 12: [1,1']Binaphthalenyl-3,4-dione:

20 Orange solid; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.40 (1H, dd, J = 1.5, 7.5 Hz), 8.00 (1H, d, J = 8.1 Hz), 7.96 (1H, d, J = 8.1 Hz), 7.72 (1H, d, J = 8.4 Hz), 7.62 (1H, d, J = 7.2 Hz), 7.57 (1H, d, J = 7.8 Hz), 7.53-7.42 (4H, m), 6.83 (1H, d, J = 8.3 Hz), 6.55 (1H, s); HPLC: 8.27 min.

Example 13: 4-(3,5-Dichloro-phenyl)-[1,2]naphthoquinone:

Orange solid; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.23 (1H, dd, J = 1.8, 7.2 Hz), 7.67-7.56 (2H, m), 7.53 (1H, m), 7.41 (1H, m), 7.33 (1H, m), 7.20 (1H, d, J = 7.5 Hz), 6.40 (1H, s); HPLC: 9.0 min.

25 Example 14: 4-(3-Nitro-phenyl)-[1,2]naphthoquinone:

Orange solid; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.41 (1H, d, J = 7.2 Hz), 8.34 (1H, s), 8.27 (1H, m), 7.78 (2H, m), 7.63 (2H, m), 7.15 (1H, d, J = 7.7 Hz), 6.46 (1H, s); HPLC: 5.78 min.

Examples 15 to 17:

30 The compounds of examples 15 to 17 were prepared substantially in accordance with the procedures disclosed in Barton, D.H.R.; Brewster, A.G.; Ley, S.V.; Read, C.M.;

Rosenfeld, M.N. *J. Chem. Soc. Perkin Trans. I* **1981**, 1473-1476, which procedures are incorporated herein by reference.

**Example 15:** 6-Benzoyl-[1,2]naphthoquinone:

Orange solid;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.23 (1H, d,  $J = 7.8$  Hz), 7.86 (1H, dd,  $J = 1.5, 7.8$  Hz), 7.83-7.79 (3H, m), 7.67 (1H, m), 7.57-7.51 (3H, m), 6.54 (1H, d,  $J = 10.2$  Hz); HPLC: 5.93 min.

**Example 16:** 5,6-Dioxo-5,6-dihydro-naphthalene-1-carboxylic acid methyl ester:

This compound was prepared using 5-carbomethoxy-2-naphthol as a starting material. The starting material was prepared according to the method of Anderson, L.C.; Thomas, D.G. *J. Am. Chem. Soc.* **1943**, 65, 234-238. Orange solid;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.62 (1H, d,  $J = 11$  Hz), 8.29 (1H, d,  $J = 7.8$  Hz), 8.20 (1H, d,  $J = 7.8$  Hz), 7.58 (1H, t,  $J = 7.8$  Hz), 6.56 (1H, d,  $J = 11$  Hz), 3.99 (3H, s); HPLC: 3.69 min.

**Example 17:** 5,6-Dioxo-5,6-dihydro-naphthalene-2-carboxylic acid methyl ester:

This compound was prepared using 6-carbomethoxy-2-naphthol as a starting material. The starting material was prepared according to the method of Anderson, L.C.; Thomas, D.G. *J. Am. Chem. Soc.* **1943**, 65, 234-238. Orange solid;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17 (2H, m), 8.05 (1H, s), 7.52 (1H, d,  $J = 10.2$  Hz), 6.53 (1H, d,  $J = 10.2$  Hz), 3.99 (3H, s); HPLC: 3.61 min.

**Example 18:** 7-Hydroxy-[1,2]naphthoquinone:

This compound was prepared substantially in accordance with the procedures disclosed in Teuber, H.-J.; Gotz, N. *Chem. Ber.* **1954**, 1236-1251, which procedures are incorporated herein by reference. Red solid;  $^1\text{H}$  NMR (300 MHz,  $\text{DMSO}-d_6$ )  $\delta$  10.50 (1H, broad s), 7.56 (1H, d,  $J = 9.8$  Hz), 7.40 (1H, d,  $J = 8.1$  Hz), 7.31 (1H, d,  $J = 2.7$  Hz), 7.05 (1H, dd,  $J = 8.1, 2.7$  Hz), 6.16 (1H, d,  $J = 9.9$  Hz); Anal. Calcd. For  $\text{C}_{10}\text{H}_6\text{O}_3 \cdot 0.1\text{H}_2\text{O}$ : C, 68.26; H, 3.55. Found: C 67.96, 67.89; H, 3.64, 3.65.

**ASSAYS FOR BIOLOGICAL ACTIVITY**

**Method A:**

*Phosphatase assay using pNPP as substrate:*

CD45 enzyme was obtained from BIOMOL (Plymouth Meeting, PA). Phosphatase activity was assayed in a buffer containing final concentrations of 25 mM imidazole at pH 7.0, 50 mM NaCl, 2.5 mM ethylenediaminetetraacetic acid ("EDTA"), 5 mM dithiothreitol ("DTT") and 10  $\mu\text{g}/\text{mL}$  bovine serum albumin ("BSA") using pNPP as a substrate.

Compounds were tested in a range from 30 to 0.01  $\mu$ M, with a final concentration of 1 or 5% dimethylsulfoxide ("DMSO"), depending on the compound solubility. Activity was measured by following the increase in absorbance at 405 nm using a SpectraMax Plus spectrophotometric plate reader (Molecular Devices, Sunnyvale, CA).

5 Method B:

*Cytotoxicity Assay:*

Calcein-AM (Molecular Probes, Eugene, OR) uptake, as a quantitative measure of cell viability, was used to evaluate the toxic effect of compounds on T cells. Briefly, PBMC were treated for 3-7 days with 3-10  $\mu$ g/ml PHA, a potent T-cell mitogen, to preferentially expand the T-cell population. (Bradley, Linda M. *Cell Proliferation in Selected Methods in Cellular Immunology*, Eds. Mishell, B.B. and Shiigi, S.M., W.H. Freeman and Co., San Francisco, 1980.)

The T-cell lymphoblasts were purified by separation over Lymphoprep, plated at  $2 \times 10^5$ /well in a round bottom 96-well plate containing RPMI with compound and incubated overnight at 37 °C in an incubator containing 5% CO<sub>2</sub>. The dilution scheme and culture media were the same as those used in the T-cell proliferation assay. After the incubation period, cells were washed with Dulbecco's phosphate- buffered saline (D-PBS) and incubated with 1  $\mu$ M Calcein-AM for 30-45 min in D-PBS as described in the technical sheet provided with The LIVE/DEAD Viability/Cytotoxicity Kit from Molecular Probes. Percent viability was assessed on a fluorescent plate reader (excitation filter 485/20 nm; emission filter 530/25 nm) where the 100% control value is the fluorescence intensity observed in the absence of test compound.

Method C:

*Phosphatase assay using lck 10-mer as substrate:*

Phosphatase activity was assayed in 96 well plates in a buffer containing final concentrations of 25 mM HEPES at pH 7.2, 5 mM DTT and 10  $\mu$ g/mL BSA, using the *lck* carboxy-terminal peptide TEGQpYQPQP as the substrate (Cho, H., Krishnaraj, R., Itoh, M., Kitas, E., Bannwarth, W., Saito, H., Walsh, C.T. 1993. Substrate specificities of catalytic fragments of protein tyrosine phosphatases (HPTPb, LAR, and CD45) toward the phosphotyrosylpeptide substrates and thiophosphotyrosylated peptides as inhibitors. *Protein Science* 2:977-984). Compounds were tested in a range from 30 to 0.01  $\mu$ M in a final concentration of 5% DMSO. Enzyme was incubated with substrate, with or without



compound, at room temperature for 1.5 h. At the end of the incubation period, BIOMOL "Green Reagent" (BIOMOL, Plymouth Meeting, PA) was added to each well, the plates incubated at room temperature for 30 min and absorbance read at 620 nm.

#### Method D:

#### 5 *Cell isolation and T cell proliferation assay:*

Whole blood was obtained from healthy human blood donors. Peripheral blood mononuclear cells ("PBMC") were isolated using Lymphoprep density-gradient centrifugation (Nycomed Amersham, Oslo, Norway), washed, counted and resuspended at  $2 \times 10^6$  cells/mL in RPMI 1640 medium containing glutamine, 0.1 mg/mL gentamycin and 10% heat  
 10 inactivated human serum. PBMC were transferred to 96-well plates ( $2 \times 10^5$  cells/well) containing compound or vehicle control, with the final concentration of DMSO not to exceed 0.3%, and incubated for 1 hour before addition of the activating anti-CD3 antibody, OKT3 (30 ng/mL). After 24 hours in culture, the cells were pulsed with [ $^3$ H]thymidine (1  $\mu$ Ci/well) overnight and harvested the next day onto 96-well Packard GF/C filter plates using a Packard  
 15 Cell Harvester (Packard Instruments, Meriden, CT). The filter plate was dried, the bottom of the plate sealed, 25  $\mu$ L of Microscint 20 scintillation fluid added to each well, the top of the plate sealed with TopSeal-A, and the plate counted on a Packard TopCount. The data from the TopCount is transferred into Excel 5 (Microsoft, Redmond, WA) and formatted for EC<sub>50</sub> determination using Prism software (GraphPad Software, San Diego, CA).

20 Table 1 shows the inhibition of CD45 activity in the pNPP assay and the *lck* assay certain compounds of the present invention. Inhibition in the T cell proliferation assay, as well as results from T cell cytotoxicity assay are shown.


Table 1:

Example. No.	pNPP IC <sub>50</sub> ( $\mu$ M)	lck IC <sub>50</sub> ( $\mu$ M)	T cell prolif. IC <sub>50</sub> ( $\mu$ M)	CC <sub>50</sub> ( $\mu$ M)
1	3	>30	7	>30
2	2	ND	>30	30
3	1.2	4.2	>30	ND
4	1.2	4.9	>30	>30
5	10	>30	>30	>30
6	8.7	>30	22	>30
7	5	19	1.5	>30
8	2.9	20	2	16

Example. No.	pNPP IC <sub>50</sub> ( $\mu$ M)	Ick IC <sub>50</sub> ( $\mu$ M)	T cell prolif. IC <sub>50</sub> ( $\mu$ M)	CC <sub>50</sub> ( $\mu$ M)
9	8	>30	0.3	12.4
10	7.7	>30	0.11	3
11	5	>30	0.15	12
12	22.5	>30	3.2	>30
13	5.5	ND	0.3	5.5
14	7.9	>30	0.2	4
15	22	>30	11	>30
16	11	>30	3.5	>30
17	7	>30	7	>30
18	4.9	ND	>30	>30

**CLAIMS**

1. A method for treating immunologically-related diseases, autoimmune disorders and organ graft rejection comprising administering to a subject suffering therefrom an effective amount of a compound in accord with structural diagram I:



I

or tautomers thereof or pharmaceutically-acceptable salts thereof:

wherein:

Q¹ at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C₁-C₃)alkyl and C(O)phenyl.


Q² is selected from hydrogen, halogen, O-(C₁-C₃)alkyl, O-(C₁-C₃)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO₂ or halogen, and indolyl may be substituted with (C₁-C₃)alkyl or phenyl.

2. A method according to Claim 1, wherein in a compound in accord with structural diagram I:

Q² is selected from O-methyl, O-ethyl, O-CH₂CH=CH₂, 3-(N-methyl-indole), 3-(2-phenyl-indole), 1-naphthyl, phenyl, 2-chlorophenyl, 4-bromophenyl, 3,5-dichlorophenyl and 3-nitrophenyl, and

Q¹ is hydrogen.

3. A pharmaceutical composition for use in the method of Claim 1, comprising a pharmaceutically-acceptable excipient or diluent together with a compound in accord with structural diagram I:



I

or tautomers thereof or pharmaceutically-acceptable salts thereof:

wherein:

$Q^1$  at each occurrence is independently selected from hydrogen, hydroxy, halogen,  $C(O)O(C_1-C_3)alkyl$  and  $C(O)phenyl$ .

$Q^2$  is selected from hydrogen, halogen,  $O-(C_1-C_3)alkyl$ ,  $O-(C_1-C_3)alkenyl$ , phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with  $NO_2$  or halogen, and indolyl may be substituted with  $(C_1-C_3)alkyl$  or phenyl.

4. A compound selected from:

4-(4-bromo-phenyl)-[1,2]naphthoquinone;

4-(3,5-dichloro-phenyl)-[1,2]naphthoquinone;

4-(3-nitro-phenyl)-[1,2]naphthoquinone;

5,6-dioxo-5,6-dihydro-naphthalene-1-carboxylic acid methyl ester, and

5,6-dioxo-5,6-dihydro-naphthalene-2-carboxylic acid methyl ester.

5. A pharmaceutical composition comprising an effective amount of a compound according to Claim 4, and a pharmaceutically-acceptable excipient or diluent.

6. A method for treating immunologically-related diseases, autoimmune disorders and organ graft rejection comprising administering to a subject suffering therefrom an effective amount of a compound according to Claim 4.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number  
**WO 01/045681 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/122**,  
31/235, 31/404, A61P 37/06, A61K 31/12, 31/40, C07C  
49/637

19850-5437 (US). **URBANEK, Rebecca** [US/US];  
1800 Concord Pike, Wilmington, DE 19850-5437 (US).  
**VEALE, Chris, Allan** [US/US]; 1800 Concord Pike,  
Wilmington, DE 19850-5437 (US).

(21) International Application Number: PCT/GB00/04872

(74) Agent: **DENERLEY, Paul, Millington**; AstraZeneca,  
Global Intellectual Property, P.O. Box 272, Mereside,  
Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(22) International Filing Date:  
18 December 2000 (18.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/172,786 21 December 1999 (21.12.1999) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except MG, US*): **AS-  
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIM-  
ITED** [GB/GB]; 15 Stanhope Gate, London W1Y 6LN  
(GB).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): **CHAPDELAINE,  
Marc, Jerome** [US/US]; 1800 Concord Pike, Wilm-  
ington, DE 19850-5437 (US). **KNAPPENBERGER,  
Katherine** [US/US]; 1800 Concord Pike, Wilmington,  
DE 19850-5437 (US). **STEELMAN, Gary** [US/US];  
1800 Concord Pike, Wilmington, DE 19850-5437 (US).  
**SUCHARD, Suzanne** [US/US]; 1800 Concord Pike,  
Wilmington, DE 19850-5437 (US). **SYGOWSKI,  
Linda** [US/US]; 1800 Concord Pike, Wilmington, DE

— with international search report


(88) Date of publication of the international search report:  
12 September 2002

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



WO 01/045681 A3

(54) Title: NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS



(I)

(57) Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q<sup>1</sup> at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C<sub>1</sub>-C<sub>3</sub>) alkyl and C(O)phenyl, and Q<sup>2</sup> is selected from hydrogen, halogen, O-(C<sub>1</sub>-C<sub>3</sub>)alkyl, O-(C<sub>1</sub>-C<sub>3</sub>)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO<sub>2</sub> or halogen, and indolyl may be substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl or phenyl.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 00/04872

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/122 A61K31/235 A61K31/404 A61P37/06 A61K31/12  
A61K31/40 C07C49/637

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 866 569 A (MJALLI ET. AL.) 2 February 1999 (1999-02-02) column 1, paragraph 1; claims; examples	1-6
A	P. PERUMAL ET. AL.: "Oxidation with Halophenols and highly Substituted Phenols with Lead (IV) Acetate" SYNTHESIS, vol. 1980, no. 11, November 1980 (1980-11), pages 943-5, XP001026188 page 944, compounds 1a and 2a ----- -/-	1-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

14 January 2002

Date of mailing of the international search report

30/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Helps, I

## INTERNATIONAL SEARCH REPORT

Intern I Application No  
PCT, JP 00/04872

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A. TAKUWA ET. AL.: "The Addition of Alcohol to 1,2-Naphthoquinone Promoted by Metal Ions. A Facile Synthesis of 4-Alkoxy-1,2-Naphthoquinones" BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 59, September 1986 (1986-09), pages 2959-61, XP002142395 page 2959, compounds 2a-2f -----	1-6
A	T. ITAHARA: "Oxidative Coupling of Quinones and Aromatic Compounds by Palladium (II) Acetate." JOURNAL OF ORGANIC CHEMISTRY, vol. 50, 1985, pages 5546-50, XP002044654 page 4455, Table I, compounds 8a and 8c -----	1-6
A	J.C. HENRION ET. AL.: "Condensation Indole-1,2-naphthoquinone. Recherche des Conditions Optimales dans la Préparation d'une Nouvelle Série de 4-(3-Indolyl)-1,2-naphthoquinones." BULLETIN DES SOCIÉTÉS CHIMIQUES BELGES, vol. 105, no. 7, 1996, pages 415-8, XP001026771 page 416, compounds 3a-3e -----	1-6
A.	A.N. GRINEV ET. AL.: "Synthesis of bis(diethylaminoethyl)-1,2-dimethyl-8-oxoindeno[2,1-b]pyrrolo[3,5-dicarboxylate." CHEMISTRY OF HETEROCYCLIC COMPOUNDS (ENGLISH TRANSLATION), vol. 19, 1983, pages 876-9, XP001026781 page 877, compound no. 1 -----	1-6
T	R.A. URBANEK ET. AL.: "Potent Reversible Inhibitors of the Protein Tyrosine Phosphatase CD45" JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2001, pages 1777-93, XP001014517 tables 1-3 -----	1-6

# INTERNATIONAL SEARCH REPORT

Intern: if Application No

PCT, <sup>us</sup> 00/04872

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5866569	A	02-02-1999	US 5723451 A	03-03-1998